NCT04827407 (LASSO) is a NA clinical trial of Efferon LPS hemoperfusion in Septic Shock, sponsored by Efferon JSC.

Who is sponsoring NCT04827407?

NCT04827407 is sponsored by Efferon JSC.

What drugs are being tested in NCT04827407?

Interventions in NCT04827407: Efferon LPS hemoperfusion.

What condition does NCT04827407 study?

NCT04827407 studies Septic Shock.

Is NCT04827407 still recruiting?

NCT04827407 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT04827407: LASSO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipopolysaccharide Adsorption At Septic Shock

Completed NA Last updated 19 September 2024

What this trial tests

NA trial testing Efferon LPS hemoperfusion in Septic Shock in 58 participants. Completed in 30 August 2022.

Timeline

23 March 2021

Primary endpoint
30 March 2022

30 August 2022

Quick facts

Lead sponsor	Efferon JSC
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	23 March 2021
Primary completion	30 March 2022
Estimated completion	30 August 2022
Sites	4 locations across Russia

Drugs / interventions tested

Efferon LPS hemoperfusion

Conditions studied

Septic Shock — all drugs for Septic Shock →

Sponsor

Efferon JSC

Who can join

Adults 18 to 75, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\\or excess of cytokines improve treatment outcomes in patients with septic shock. The main purpose of the study is to obtain new data on the efficacy and safety of the Efferon LPS device in extracorporeal therapy in patients with abdominal sepsis complicated by septic shock.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

HEMOPERFUSION USING THE LPS-SELECTIVE MESOPOROUS POLYMERIC ADSORBENT IN SEPTIC SHOCK: A MULTICENTER RANDOMIZED CLINICAL TRIAL.
Rey S, Kulabukhov VM, Popov A, Nikitina O, et al · · 2023 · cited 6× · PMID 37018802 · DOI 10.1097/shk.0000000000002121
44th International Symposium on Intensive Care & Emergency Medicine.
· 2025 · cited 3× · PMID 40098153 · DOI 10.1186/s13054-025-05304-y

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other Efferon JSC trials

Trials by the same sponsor.

NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
NCT07383597 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease · NA · not yet recruiting
NCT07259668 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns · recruiting
NCT07248930 — Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04827407 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Efferon JSC
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04827407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing